Has Eli Lilly Stock Peaked?
Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is in good financial shape but investors may be worried about its high valuation.
GlobalData on MSN18h
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400mEli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
Key Takeaways Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
GlobalData on MSN2d
Eli Lilly targets Scorpion Therapeutics to expand reach in oncologyAfter selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
Lilly gave hopeful income projections for 2025 ranging from $58 billion to $61 billion, therefore showing a midpoint rise of ...
The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback